{"id":"flotufolastat-f18","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Flotufolastat F18 works by inhibiting the SARS-CoV-2 main protease, which is essential for the viral replication. This inhibition prevents the virus from replicating and spreading within the host. By targeting this specific enzyme, Flotufolastat F18 aims to reduce the viral load and alleviate symptoms in patients infected with COVID-19.","oneSentence":"Flotufolastat F18 is a small molecule that targets the SARS-CoV-2 main protease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:38.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT06881823","phase":"PHASE1, PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06105918","phase":"PHASE1","title":"Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-11-29","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":6},{"nctId":"NCT06862856","phase":"","title":"Flotufolastat F 18 PET in Men With Very Low PSA Recurrence","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-20","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen","enrollment":50},{"nctId":"NCT07185165","phase":"PHASE2","title":"An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-10-09","conditions":"Prostate Carcinoma","enrollment":81},{"nctId":"NCT07220720","phase":"PHASE2","title":"POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-11-04","conditions":"Prostate","enrollment":30},{"nctId":"NCT05779943","phase":"PHASE2","title":"Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-04-27","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":20},{"nctId":"NCT06389786","phase":"NA","title":"Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-11","conditions":"Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":50},{"nctId":"NCT04186845","phase":"PHASE3","title":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-05-04","conditions":"Prostate Cancer","enrollment":391},{"nctId":"NCT07149831","phase":"PHASE1","title":"A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-06-07","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT07115277","phase":"NA","title":"Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-03-14","conditions":"Prostate Cancer","enrollment":121},{"nctId":"NCT06580015","phase":"NA","title":"[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-03-25","conditions":"Prostate Carcinoma","enrollment":20},{"nctId":"NCT07069465","phase":"EARLY_PHASE1","title":"Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging","status":"COMPLETED","sponsor":"Urology Clinics of North Texas","startDate":"2024-06-15","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06865768","phase":"PHASE2","title":"An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-18","conditions":"Prostate Carcinoma","enrollment":90},{"nctId":"NCT05852041","phase":"EARLY_PHASE1","title":"rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-06-07","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06813898","phase":"EARLY_PHASE1","title":"An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-02-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["POSLUMA®"],"phase":"phase_2","status":"active","brandName":"Flotufolastat F18","genericName":"Flotufolastat F18","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flotufolastat F18 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}